146 related articles for article (PubMed ID: 11432619)
21. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
22. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D
Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071
[TBL] [Abstract][Full Text] [Related]
24. Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin.
Kermani IA; Dehdilani M; Dolatkhah R
Asian Pac J Cancer Prev; 2007; 8(3):367-71. PubMed ID: 18159969
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
26. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
28. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
30. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia.
Gjedde SB; Hansen MM
Leuk Lymphoma; 1996 Apr; 21(3-4):317-20. PubMed ID: 8726413
[TBL] [Abstract][Full Text] [Related]
33. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
34. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
O'Brien ME; Matutes E; Cunningham D; Hill M; Emmett E; Ellis PA; Milan S; Hickish T; Mercieca J; Catovsky D
Leuk Lymphoma; 1994; 14 Suppl 2():17-23. PubMed ID: 7881347
[TBL] [Abstract][Full Text] [Related]
36. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
37. Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.
Wang WT; Zhu HY; Wu YJ; Xia Y; Wu JZ; Wu W; Liang JH; Wang L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2018 Mar; 144(3):449-457. PubMed ID: 29299750
[TBL] [Abstract][Full Text] [Related]
38. Chronic lymphocytic leukemia in the elderly population.
Rai KR
Clin Geriatr Med; 1997 May; 13(2):245-9. PubMed ID: 9115449
[TBL] [Abstract][Full Text] [Related]
39. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
40. The management of chronic lymphocytic leukemia at a single centre over a 24-year period: prognostic factors for survival.
Karmiris T; Rohatiner AZ; Love S; Carter M; Ganjoo RK; Amess J; Norton AJ; Lister TA
Hematol Oncol; 1994; 12(1):29-39. PubMed ID: 7515019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
